Does This Marijuana Breakthrough Make This Marijuana Stock A Buy?

TL;DR

The marijuana breakthrough does not make GW Pharmaceuticals a buy according to the analysis, which calls the company a “stay-away story.” About 5,400 U.S. patients have Dravet syndrome, and applying Sativex’s $16,000 price suggests an annualized sales pace near $86 million, limited beside GW’s $1.8 billion market cap. Read on for the sales assumptions, pipeline concerns, and competitive risks behind that conclusion.

Transcript

these patient populations are fairly small right and again this goes to what you know what kind of what we were talking about before words you're trying to figure out you know how should I think about this company and how should I think about this development at the company you know there's only 5,400 patients in the United States with drivet syndr... Read More

Key Insights

• 😀 GW Pharmaceuticals faces a small patient population for its CBD medication, limiting its sales potential.
• ✋ The company's market cap suggests high expectations, but its commercial opportunities seem limited in the near future.
• ✳️ Competition from dispensaries selling cheaper CBD extracts and potential competitors' RD efforts pose risks to GW Pharmaceuticals.
• ❓ The marijuana market is uncertain and complex due to the legal status of cannabis and varying regulations in different states.

Questions & Answers

Q: Does this marijuana breakthrough make GW Pharmaceuticals stock a buy?

No. The analysis describes GW Pharmaceuticals as a “stay-away story” because its initial sales potential appears limited relative to its $1.8 billion market cap, while competition and uncertain peak-sales estimates create additional risks.

Q: How large is the U.S. patient population for Dravet syndrome?

The discussion estimates that about 5,400 patients in the United States have Dravet syndrome. That relatively small population limits the immediate sales opportunity for a treatment targeting the condition.

Q: How was the estimated $86 million annualized sales pace calculated?

The estimate applies a $16,000 price to approximately 5,400 U.S. patients with Dravet syndrome. That produces an annualized sales pace of roughly $86 million.

Q: What is Sativex, and why is its price relevant?

Sativex is GW Pharmaceuticals’ other marijuana drug, available in Europe. The analysis uses the approximately $16,000 amount the company receives for Sativex as a pricing assumption for estimating the Dravet syndrome opportunity.

Q: What sales could the drug potentially generate with the LGS indication included?

The speakers suggest the drug could theoretically generate between $100 million and $200 million if the LGS indication is included. They stress that this is a guesstimate and recommend keeping peak-sales expectations restrained.

Q: Does GW Pharmaceuticals have strong follow-on indications or a promising pipeline?

The analysis does not identify follow-on indications or pipeline assets with especially large sales potential. It concludes that GW Pharmaceuticals does not appear to have much commercial opportunity over the next few years.

Q: How could dispensaries compete with GW Pharmaceuticals?

Dispensaries in states selling extracts high in CBD could capture some of GW Pharmaceuticals’ potential market share. The speakers expect those dispensary products would probably be cheaper.

Q: What other risks could limit GW Pharmaceuticals’ investment potential?

Evidence that CBD helps epileptic patients could fuel research and development by competitors, leading to multiple competing therapies. The marijuana market also carries uncertainty because cannabis is a controlled substance while some states support it and the FDA is evaluating CBD compounds from GW and competitors such as Insys.

Summary & Key Takeaways

• GW Pharmaceuticals has a market cap of $1.8 billion but only has a limited patient population for its CBD medication, Sativex, earning an estimated annualized sales pace of $86 million.

• There doesn't seem to be significant commercial opportunity for GW Pharmaceuticals in the next few years, and their pipeline does not indicate any promising developments.

• The company may face competition from dispensaries selling CBD extracts, potentially impacting their market share and sales. Additionally, competitors' RD efforts could introduce alternative therapies.